- Federal agencies extended telemedicine flexibilities for controlled substances to December 31, 2026.
- The extension prevents a sudden “telehealth cliff” and preserves access to medications for vulnerable populations.
- DEA and HHS will use this period to finalize permanent telemedicine prescribing regulations while reinforcing safety measures.
Telemedicine flexibilities allow DEA-registered practitioners to prescribe Schedule II–V controlled substances via telemedicine without a prior in-person medical evaluation. HHS and DEA extended those flexibilities through December 31, 2026, ensuring patients keep access to needed medications while permanent regulations are under development (hhs.gov).
The extension affects patients who rely on telehealth to receive controlled medications: seniors, rural residents, people with disabilities, those receiving treatment for mental health or substance use disorders. Prior lapses triggered steep drops in telemedicine visits—a 24 percent drop after Medicare flexibilities lapsed in September 2025 (hhs.gov). The extension upholds continuity of care and prevents patients from hitting a telehealth cliff mid-stream.
DEA and HHS are using this extension period to finalize permanent rules, including proposed special registration for telemedicine and specific safeguards. They plan to issue regulations that codify when and how controlled medications can be prescribed by telehealth—balancing access and safety (hhs.gov). Providers should review their compliance procedures now (deadiversion.usdoj.gov).
What are telemedicine flexibilities?
Telemedicine flexibilities let DEA-registered practitioners prescribe Schedule II–V controlled substances via telemedicine—including video or, in some cases, audio-only—without a prior in-person visit, as long as other legal requirements are met.
How long do the telemedicine flexibilities last?
The flexibilities are temporarily extended through December 31, 2026, giving agencies time to finalize permanent telehealth prescribing rules.
Why did federal agencies extend the telemedicine flexibilities?
They extended the flexibilities to avert a sudden telehealth cliff, maintain patient access to controlled medications, and avoid disruptions in care while developing permanent regulations.
Who benefits from these extended telemedicine flexibilities?
Patients in rural areas, seniors, those with disabilities, and individuals with mental health conditions or substance use disorder benefit most, as they often rely on telehealth to receive controlled-medication prescriptions.
Are there safeguards still in place under these telemedicine flexibilities?
Yes. Prescriptions must be for legitimate medical purposes, issued by licensed practitioners, and comply with federal and state law. Agencies emphasize provider compliance and risk monitoring during this extension period.
Not medical advice. Telehealth services, prescriptions, and insurance coverage vary by state and provider. Verify a provider’s licensing and consult a qualified professional before making care decisions.